logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
26/08/2025
Lai publishes the results of the second obesity trial of Orforglipron, the drug resulted in a 9.6% weight loss for obese and diabetic patients, and plans to apply for approval of the weight loss drug in 2025.
Latest
1 m ago
Chaojie Group (301005.SZ) releases its first half year performance, with a net profit attributable to the parent company of 21.72 million RMB, an increase of 21.86%.
1 m ago
Tianchen Medical: Net profit in the first half of the year increased by 67.1% year on year, planning to distribute 5 yuan per 10 shares.
2 m ago
Hualian Holdings (000036.SZ) released its performance for the first half of the year, with a net profit attributable to the parent company of 2.0356 million yuan, a year-on-year decrease of 93.84%.
2 m ago
Canadian Geese: Costs have increased due to marketing and store investment, but are expected to decrease as scale expands.
2 m ago
Canadian geese: costs have increased due to marketing and store investments, but are expected to decrease as scale expands.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.